Confidential mandate

Security-Product Commercialisation and Assurance-Integrity Adviser

Planned Hiring / New

Security-Product Commercialisation and Assurance-Integrity Adviser mandate in Bengaluru, India · Cybersecurity Products

A security-product committee needs independent challenge of commercialisation choices and assurance integrity; this six-month adviser tests product claims, customer value and fee incentives while product executives and authorised testing teams retain decisions and delivery responsibility.

The mandate

The committee repeatedly asks how to commercialise a security product without overstating the assurance it provides or allowing revenue incentives to distort testing judgement. A persuasive product demonstration may not establish useful detection, safe operation or consistent customer value. The adviser will challenge those claims and tradeoffs at practice-director scope, not substitute a product retainer for an enterprise security-chief seat.

Five days monthly support evidence review, product and delivery interviews and a written committee challenge. Product committee attendance is included. Demonstration records and claim substantiation arrive six working days ahead; off-cycle questions are acknowledged within a business day and receive reasoned advice within four when the evidence is complete. New validation testing or GTM execution requires separately authorised work.

The commercialisation review runs six months from 19 October 2026. Renewal belongs to the committee chair and must identify unresolved product-evidence or incentive questions, with independence reassessed. Bengaluru workshops alternate with remote preparation. The term should leave product owners able to distinguish a commercially attractive claim from a supported one, not dependent on an external adviser to approve routine messaging.

Product challenge grants no line authority over engineers, testers or sales. The adviser takes no executive responsibility for product release, customer claims or assessment delivery. Executives approve those decisions, and authorised testing owners establish scope. Advice must expose the cost of proving a claim and the risk of selling beyond evidence while recognising that excessive caution can also obscure genuine product value.

Concurrent retainers are acceptable outside competing security products or reviewed customer assurance matters. A product-reseller interest, testing fee dependent on the recommendation or paid preparation of the same claim creates a conflict. The adviser must disclose these links before reviewing evidence and agree recusal or restricted access. Independent challenge cannot become a concealed sales channel for subsequent validation or implementation services.

What you will own

  • Test product capability claims against observed evidence and stated operating conditions, identifying where a demonstration cannot support the broader assurance proposed in commercial materials.
  • Question commercialisation priorities using customer security value, proof burden and delivery capacity rather than accepting revenue potential as sufficient justification for a product promise.
  • Shape comparisons of product, service and hybrid offers that expose quality cost, independence risks and the evidence required before the committee chooses a route.
  • Press testing and product owners to distinguish validation scope from sales messaging, preserving written authorisation and the limitations of any assessment used to support a claim.
  • Challenge incentive proposals where assessment renewal or product sales could reward softened findings, recommending practical governance rather than relying on a general independence statement.
  • Recommend claim-review gates and evidence expiry triggers that keep commercial positioning credible after product changes, new use cases or a different customer operating context.

Candidate qualifications

  • Show at least ten years in cybersecurity with substantive product, offensive-security or practice leadership and personally evidenced commercial decisions. Present a product claim or launch choice you challenged, the missing proof and the resulting action. Explain the proof requirement you recommended before commercial release and distinguish the committee's product decision from the asset owner's test authorisation and management's customer-claim approval.
  • Demonstrate strong understanding of authorised red or purple-team evidence, product validation and assurance limitations. Explain a case where a limited assessment was at risk of being marketed as broader capability, and show how you narrowed or strengthened the claim while preserving genuine customer value.
  • Bring security-product economics and GTM judgement supported by delivery or customer outcomes. Describe how you compared proof cost, specialist capacity and commercial opportunity, including a recommendation that delayed or changed an offer. AI, DevSecOps or security-operations exposure should be evidenced through actual validation or adoption rather than broad terminology.
  • Prove independent advice with reseller, customer, testing or implementation fee conflicts handled in practice. Disclose current commercial interests and demonstrate capacity for five reserved days monthly. The adviser must be comfortable recording a disagreement with product leadership while leaving release, customer claims and testing execution with authorised internal owners.

Application

Applications for this mandate are received in one way only: through the India Board Terminal's application process. It is automated end to end. Your Executive Passport travels to the mandate holder in its confidential form, your answers to the three questions below are read before anything else in your file, and every stage that follows is recorded on your applications page.

There is no address to write to and no intermediary to call. The mandate holder reads what the Terminal delivers and nothing else, which is what keeps the process the same for every applicant and keeps your name out of it until you release it. Applications close on 11 October 2026. Mandate reference PCT-ADV-2026-IND-58.

More seats like this one

Every live mandate, by seat →

This mandate is confidential. The client is named only under a mutual NDA, and your own record is never listed, sold or shown to a company under your name until you release it for this specific mandate.